News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results For AST-OPC1 5/24/2016
Celsion (CLSN) Announces Presentation Of OVATION Study Clinical Trial Design At Upcoming ASCO 2016 Meeting 5/24/2016
Eli Lilly (LLY) Projects 20 New Product Launches in 10 Years with 20 Possible Expansions 5/24/2016
Boehringer Ingelheim Release: IL-23 Inhibitor Risankizumab Induces Remission In Phase II Study In Patients With Moderate-To-Severe Crohn’s Disease 5/24/2016
Independent Phase II And III Clinical Studies On 22nd Century Group, Inc.'s Smoking Cessation Technology Highlighted On New Heracles Website 5/24/2016
AbbVie (ABBV) Release: IL-23 Inhibitor Risankizumab Induces Remission In Phase II Study In Patients With Moderate-To-Severe Crohn's Disease 5/24/2016
Isofol Medical AB Announces Successful Meetings With European And US Regulatory Authorities Regarding The Design Of A Pivotal Phase II Clinical Trial Of Isofol's Lead Drug Candidate, Modufolin 5/24/2016
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2016
Ipsen (IPN.PA)’s Partner Exelixis (EXEL) Announced Results From Randomized Phase 2 Trial CABOSUN That Demonstrate That Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 5/24/2016
Exelixis (EXEL)' Cabozantinib Met Primary Endpoint in Phase II Renal Cell Carcinoma Study 5/23/2016
Synthetic Biologics (SYN) Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 5/23/2016
Vtesse Advances Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease With Dose Selection For Evaluation In Second And Final Portion Of Trial And Expansion Into Europe 5/23/2016
ResMed (RMD) Release: Adaptive Servo-Ventilation (ASV) Therapy Suggests Positive Cardiovascular Outcomes For People With Sleep-Disordered Breathing And Heart Failure With Preserved Ejection Fraction In Phase II Study 5/23/2016
Medimetriks Pharmaceuticals, Inc. Announces The Results Of A Successful Phase 2 Trial Of MM36 In Atopic Dermatitis; Study Results And Design Published In The Journal Of The American Academy Of Dermatology (JAAD) 5/23/2016
DS Biopharma Announces DS102 Will Be Developed For Pulmonary Disorders In Addition To NASH 5/23/2016
Mast Therapeutics (MSTX) Release: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At European Society of Cardiology 3rd World Congress On Acute Heart Failure 5/23/2016
Synthetic Biologics (SYN) Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 5/23/2016
Akebia (AKBA) Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction 5/23/2016
Nemucore Medical Innovations Study Published In Molecular Pharmaceutics Furthers Understanding Of NMI-350 And Theranostics For Ovarian Cancer 5/23/2016
Cytokinetics (CYTK) Announces Presentation Of Additional Results From COSMIC-HF At Heart Failure 2016 Congress 5/23/2016
13 Massachusetts Cancer Biotechs Looking to Shake Things Up at ASCO in June 5/20/2016
Clovis Oncology (CLVS) Announces Data Presentations At 2016 ASCO Annual Meeting 5/20/2016
ViroMed Of Korea Receives U.S. Fast Track Status For Gene Therapy 5/20/2016
Santalis Announces First Subject Enrolled In Phase 2 Trial Of East Indian Sandalwood Oil (EISO) To Treat Mild To Moderate Plaque Psoriasis 5/20/2016
NovoCure Enrolls Last Patient In INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel In Recurrent Ovarian Cancer 5/20/2016
Provectus Announces Abstract Available On PV-10 Plus Radiotherapy In Melanoma 5/20/2016
Xencor Reports Complete Data Results From XmAb7195 Phase 1a Trial Showing Rapid Reduction Of Serum IgE In High IgE Atopic Subjects At American Thoracic Society 2016 International Conference 5/19/2016
Janssen R&D To Present Data From Six Compounds Including Daratumumab And Ibrutinib At The 2016 ASCO Annual Meeting 5/19/2016
AbbVie (ABBV) Demonstrates Progress In Oncology Research At ASCO 2016 Annual Meeting With Multiple Abstracts Evaluating Eight Medicines Across Cancer Types 5/19/2016
Amgen (AMGN) Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients 5/19/2016
Array BioPharma (ARRY) Announces Key Data From NRAS-Mutant Melanoma And BRAF-Mutant Colorectal Cancer ASCO 2016 Presentations 5/19/2016
Bayer (BAY) To Showcase Latest Oncology Research At ASCO 2016 5/19/2016
ProNAi Therapeutics, Inc. To Report Wolverine Phase 2 Interim Results On June 6th At ASCO 5/19/2016
Mirati Therapeutics  (MRTX) To Present Abstracts On Pipeline Programs At 2016 ASCO Annual Meeting 5/19/2016
Karyopharm (KPTI) To Present Selinexor Clinical Data At The ASCO Annual Meeting 5/19/2016
Merrimack (MACK) Announces A Leading-Edge Biomarker-Selected, Multi-Arm Basket Trial That Matches Patients With Most Appropriate Combination Regimens 5/19/2016
AbbVie (ABBV)'s Leadership In Gastroenterology Showcased At Digestive Disease Week With New HUMIRA (Adalimumab) Long-Term, Real-World Research And Promising Anti-IL-23 Antibody Late-Breaking Data 5/19/2016
Bone Therapeutics To Enhance Value Of Its Severe Osteoporosis Program By Transitioning To Allogeneic Development 5/19/2016
Infinity Pharmaceuticals Inc. (INFI) Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming European Hematology Association And ASCO Meetings 5/19/2016
uniQure (QURE) Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association 5/19/2016
BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences 5/19/2016
NovoCure Announces Presentation Of Subgroup Analysis Of PANOVA Data Showing Overall Survival Benefit Of Tumor Treating Fields Plus Gemcitabine In Advanced Pancreatic Cancer Patients 5/19/2016
NovoCure Announces Presentation Of Subgroup Analysis Of PANOVA Data Showing Overall Survival Benefit Of Tumor Treating Fields Plus Gemcitabine In Advanced Pancreatic Cancer Patients 5/19/2016
Puma Biotech (PBYI) Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting 5/19/2016
Ariad (ARIA) Announces Data Presentations At The 2016 ASCO Annual Meeting 5/19/2016
Celgene (CELG) Announces Presentations Of Investigational Studies In Solid Tumor And Blood Cancers At ASCO 2016 5/19/2016
Provectus Announces Abstract Available Online Of Trials In Progress; Abstract For Poster Presentation At ASCO Annual Meeting 5/19/2016
Alexion (ALXN) Release: Researchers To Present Late-Breaking Data On ALXN1210 In Patients With PNH At European Hematology Association Annual Congress 5/19/2016
Acceleron Pharma Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association 5/19/2016
Oncolytics Biotech Inc. (ONC.TO) Reports Preliminary Data From Randomized Phase II Study Of REOLYSIN In Non-Small Cell Lung Cancer 5/19/2016
Agenus (AGEN) Appoints Ulf Wiinberg To Board Of Directors 5/19/2016
Initial Efficacy Data For GlycoMimetics, Inc. (GLYC)’ GMI-1271 Combined With Chemotherapy In Patients With AML To Be Presented At European Hematology Association 21st Congress 5/19/2016
Novartis Pharmaceutical Corporation (NVS) To Present Pivotal Data In Hematologic And Solid Tumor Cancers At 2016 ASCO Annual Meeting 5/19/2016
Health Canada Authorizes ProMetic Life Sci (PFSCF.PK) To Proceed With Its PBI-4050 Clinical Trial In Patients With Cystic Fibrosis 5/18/2016
Merrimack (MACK) Presents Expanded Analysis From Seribantumab (MM-121) Phase 2 Breast Cancer Study At The AACR Precision Medicine Series 5/18/2016
FDA Grants IND Approval To Stemedica Cell Technologies, Inc. For A Traumatic Brain Injury Phase Ila Clinical Trial 5/18/2016
Ascendis Pharma A/S To Present At The UBS Global Healthcare Conference On May 23, 2016 5/18/2016
Synthetic Biologics (SYN) To Host Post-DDW 2016 Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 5/18/2016
Kiadis Pharma Presents Multiple Sets Of Data At The International Society For Cellular Therapy (ISCT) 2016 Annual Meeting 5/18/2016
Nordic Nanovector Announces First Patient Enrolled In The Last Cohort (Arm 4) Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients 5/18/2016
Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled 5/18/2016
Abeona Therapeutics Doses First Patient In Phase 1/2 Trial With ABO-102 Gene Therapy For Patients With Sanfilippo Syndrome Type A (MPS IIIA) 5/18/2016
Breadth And Depth Of Bristol-Myers Squibb (BMY)’s Immuno-Oncology Clinical Development Program To Be Showcased At 2016 ASCO Annual Meeting 5/18/2016
Asterias Biotherapeutics Reports First Quarter Results 5/17/2016
Sophiris Bio (SPHS) Reports First Quarter 2016 Financial Results And Key Business Highlights 5/17/2016
Xencor To Present At Upcoming Investor Conferences 5/17/2016
BioLineRx Reports First Quarter 2016 Financial Results 5/17/2016
Nivalis Therapeutics Announces First Patient Dosed In Second Phase II Study Of N91115 For Treatment Of Cystic Fibrosis 5/17/2016
Synthetic Biologics (SYN) To Host Post-DDW 2016 Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 5/17/2016
Bone Therapeutics Announces Further Positive Efficacy In ALLOB Phase I/IIA Delayed-Union Fracture Trial 5/17/2016
VM BioPharma Announces FDA Fast Track Designation Granted For Investigational Gene Therapy VM202 For Patients With Amyotrophic Lateral Sclerosis (ALS) 5/17/2016
Theranexus Reaches Its Primary Endpoint In The Proof Of Concept Trial Of THN102 In Excessive Daytime Sleepiness (EDS) 5/17/2016
GANYMED Pharmaceuticals AG To Present Exciting Phase II Clinical Data For IMAB362 In Gastroesophageal Cancer At ASCO 2016 Annual Meeting 5/17/2016
Boehringer Ingelheim Release: South Korea Is First To Approve Next Generation Lung Cancer Treatment Olmutinib (BI 1482694 / HM61713) 5/17/2016
Hansa Medical: Ongoing US Study Shows That IdeS Allows For Transplantation Of Highly Sensitized Patients 5/17/2016
Aduro Biotech (ADRO)'s Stock Craters After Pancreatic Cancer Drug Trial Misses Primary Endpoint 5/17/2016
Sorrento (SRNE) Reports Positive Data from Combined Phase II & III Clinical Study Of STI-004 5/16/2016
After Heart Drug Flunks Phase II Study, Trevena (TRVN) Makes Strategic Pivot to Focus on Pain Drugs 5/16/2016
Allergan (AGN) Shows Off Positive Mid-Stage Data for Oculeve Intranasal Tear Neurostimulator 5/16/2016
BioSight Release: Arkin Holdings And Primera Capital Lead An Investment Of $13M In Biosight For An Innovative Treatment Of Acute Leukemia 5/16/2016
BioLineRx And MaRS Innovation Sign Framework Collaboration Agreement 5/16/2016
Mundipharma And Purdue Pharma L.P. Expand Pain Pipeline With New Deal For First-In-Class Sigma-1 Antagonist (S1A Or MR309/E-52862) From ESTEVE 5/16/2016
Celsion (CLSN) Reports First Quarter 2016 Financial Results And Provides Business Update 5/16/2016
Cytokinetics (CYTK) Announces Additional COSMIC-HF Results To Be Presented At Heart Failure 2016 5/16/2016
Mast Therapeutics (MSTX) Release: Positive Interim Results From Second Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Presented At American Thoracic Society International Conference 5/16/2016
Synthetic Biologics (SYN) Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea 5/16/2016
Catabasis Pharma To Present Pre-Clinical Data Supporting CAT-2054 As A Potential Treatment For Nonalcoholic Steatohepatitis (NASH) At Digestive Disease Week 2016 5/16/2016
Afferent Pharmaceuticals Presents Updated Positive Results With AF-219 From Phase IIB Chronic Cough Study At The 2016 American Thoracic Society International Conference 5/16/2016
NeOnc Technologies Announces Initiation Of Phase 1/2a Clinical Trial Of NEO100 In Recurrent Glioblastoma Multiforme (GBM) 5/16/2016
BioNevia And Neuromax Announce Completion Of Enrollment In Phase IIb Clinical Trial Of BNV-222 5/16/2016
PledPharma Release: New Data Strengthens Claim That Pledox Does Not Negatively Interfere With The Anti-Cancer Effect Of Chemotherapy 5/16/2016
Capricor Therapeutics, Inc. Provides Corporate Update And Reports First Quarter 2016 Financial Results 5/13/2016
Humacyte Commences Phase III Clinical Trial Of Human Acellular Vessel 5/13/2016
Humacyte’s Phase II Bioengineered Blood Vessel Study Results Published in The Lancet 5/13/2016
Mirna Reports First Quarter 2016 Financial Results And Program Updates 5/13/2016
Catabasis Pharma Reports First Quarter 2016 Financial Results And Recent Corporate Highlights 5/13/2016
vTv Therapeutics Reports First Quarter Financial And Operational Results 5/13/2016
Provectus Announces Publication Of Article In Oncotarget Detailing PV-10’s Immuno-Ablative Mechanism Of Action 5/13/2016
Maxwell Biotech Venture Fund's Portfolio Company Neuromax Announce Completion Of Enrollment In Phase 2b Clinical Trial Of BNV-222 5/13/2016
Asterias Biotherapeutics Announces Closing Of Public Offering Of Common Stock And Warrants, And Exercise Of Over-Allotment Option To Purchase Additional Warrants 5/13/2016
NeuralStem Inc. To Raise $1.08 Million 5/13/2016
Bayer (BAY) Terminates Phase II Study With Riociguat In Patients with PH-IIP 5/12/2016
BrainStorm Cell Awarded $1.5 Million Non-Dilutive Grant For 2016 From Israel's Office Of The Chief Scientist 5/12/2016
aTyr Pharma Announces First Quarter 2016 Operating Results 5/12/2016
RXi Pharma (RXII) Reports First Quarter 2016 Financial Results And Highlights Recent Corporate Developments 5/12/2016
Transition Therapeutics (TTH.TO) Announces Third Quarter Fiscal 2016 Financial Results 5/12/2016
NeuralStem Inc. Announces First Patient Enrolled In Phase 2 Clinical Trial In Major Depressive Disorder 5/12/2016
Recro Pharma (REPH) Presents Clinical Data At American Pain Society 35th Annual Scientific Meeting 5/12/2016
CASI Pharmaceuticals  (CASI) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 5/12/2016
Nemucore Medical Innovations Announces NMI-350 ACOG Poster Presentation 5/12/2016
Helix Release: First Patient Dosed In Phase II Study Of L-DOS47 In Non-Small Cell Lung Cancer 5/12/2016
Braeburn Pharma, Camurus Announce Positive Mid-Stage CAM2038 Data in Patients With Opioid Use Disorder 5/11/2016
Isaac J. Bright, MD, Joins Synthetic Biologics (SYN) As Vice President, Corporate Development 5/11/2016
VistaGen Therapeutics, Inc. Announces Nasdaq Listing And Pricing Of $10.0 Million Public Offering 5/11/2016
Viking Therapeutics (VKTX) Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/11/2016
Intrexon (XON) Announces First Quarter 2016 Financial Results 5/11/2016
Viriom Announces Receipt Of Funding From The Skolkovo Foundation, ChemRar And Torrey Pines Investment To Develop Elpida, A Novel Preventive And Long-Acting Treatment Of HIV/AIDS 5/11/2016
Arrowhead Pharma (ARWR) Reports Fiscal 2016 Second Quarter Results 5/11/2016
BioTime (BTX) Reports First Quarter Results And Recent Corporate Accomplishments 5/11/2016
Osel, Inc.’s Lead Product LACTIN-V Enters Phase 2b Study To Prevent Recurrence Of Bacterial Vaginosis 5/11/2016
Medivir (MVRBF) Announces That Janssen R&D Decided To Start A Phase IIb Study Of Combinations Of Simeprevir, Odalasvir And AL-335 For The Treatment Of Hepatitis C 5/11/2016
Eiger Biopharma Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery 5/10/2016
Tobira Reports First Quarter 2016 Financial And Business Results 5/10/2016
Asterias Biotherapeutics Prices Public Offering Of Common Stock And Warrants 5/10/2016
ProNAi Therapeutics, Inc. Reports First Quarter 2016 Results 5/10/2016
BrainStorm Cell Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/10/2016
Dr. Patrick Soon-Shiong Presents Promising Results Of Novel Adenoviral Colon Cancer Vaccine In Treating End-Stage Colon Cancer At The Bank of America (BAC) Merrill Lynch 2016 Health Care Conference 5/10/2016
BioLineRx To Report First Quarter 2016 Results On May 17, 2016 5/10/2016
Verona Pharma (VRP.L) Announces Positive Results From "Add-On" Phase II Trial With RPL554 5/10/2016
Novan To Present Anti-Viral Data For Nitric Oxide Product Candidate SB206 5/10/2016
NovoCure Reports First Quarter 2016 Financial Results And Provides Company Update 5/10/2016
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA 5/10/2016
Dicerna (DRNA) Reports First Quarter 2016 Financial and Operational Results 5/10/2016
Opko Health (OPK) Reports First Quarter Financial And Operating Results 5/10/2016
Ocular Therapeutix (OCUL) Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/10/2016
GTx, Inc. (GTXI) Provides Corporate Update And Reports First Quarter 2016 Financial Results 5/10/2016
Omeros Corporation (OMER) Reports First Quarter 2016 Financial Results 5/10/2016
Aldeyra Therapeutics (ALDX) Announces Positive Results From Phase II Clinical Trial In Subjects With Noninfectious Anterior Uveitis 5/10/2016
Allergy Therapeutics plc Race with Positive Phase II Data for Hayfever 5/9/2016
Synthetic Biologics (SYN) Appoints Deb Mathews, PharmD, As Vice President, Medical Affairs 5/9/2016
Sangamo (SGMO) Presents Recent Developments From Research And ZFP Therapeutic Programs In Multiple Presentations At Annual Meeting Of The American Society Of Gene And Cell Therapy 5/9/2016
Dimension Therapeutics Announces Preclinical Data From Bayer-Partnered Hemophilia A Program At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting 5/9/2016
Galmed Pharmaceuticals First Quarter 2016 Conference Call And Webcast Scheduled For Monday, May 16th, 2016 5/9/2016
Kamada Ltd. (KMDA) Reports 2016 First Quarter Financial Results 5/9/2016
BIND Therapeutics (BIND) Reports First Quarter 2016 Financial Results And Provides Business Update 5/9/2016
Incyte (INCY) Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs 5/9/2016
The Medicines Company (MDCO) Reports First-Quarter 2016 Business And Financial Results 5/9/2016
Seres Therapeutics To Host First Quarter 2016 Financial Results And Operational Progress Conference Call And Webcast On May 16, 2016 5/9/2016
bluebird bio (BLUE) Presents Oncology And Gene Therapy Data At The ASGCT 19th Annual Meeting 5/9/2016
Aurinia (ISA.TO) Initiates First Clinical Study Of Voclosporin For Japan 5/9/2016
Epizyme (EPZM) Announces First Quarter 2016 Financial Results And Provides Update On Execution Against Multi-Year Company Vision 5/9/2016
Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy 5/9/2016
NeuroDerm (NDRM) Announces Patient Enrollment In Long-Term Safety Trial Of ND0612 For Parkinson’s Disease 5/9/2016
Azevan Pharmaceuticals Completes Enrollment In Phase 2 Clinical Study Of SRX246 In Intermittent Explosive Disorder 5/9/2016
NeuralStem Inc. Reports Fiscal First Quarter 2016 Results And Business Update 5/9/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: RGN-259 Confirms Efficacy In Signs And Symptoms Of Dry Eye 5/6/2016
Mast Therapeutics (MSTX) Reports First Quarter 2016 Financial Results And Recent Highlights 5/6/2016
Oncolytics Biotech Inc. (ONC.TO) Announces 2016 First Quarter Results 5/6/2016
Heron (HRTX) Announces First Quarter 2016 Financial Results And Recent Corporate Progress 5/6/2016
SAGE Therapeutics (SAGE) Announces First Quarter 2016 Financial Results 5/6/2016
Novaliq GmbH Announces Last Patient Enrolled In Phase 2 Clinical Trial Of Cyclasol For The Treatment Of Moderate To Severe Dry Eye Disease 5/6/2016
aTyr Pharma Appoints Grove Matsuoka As Senior Vice President, Product Programs And Planning 5/5/2016
Helsinn Announces Top-Line Results Of Its Phase Ilb Trial With Elsiglutide For The Prevention Of Chemotherapy-Induced Diarrhea In Colorectal Cancer Patients 5/5/2016
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports First Quarter 2016 Financial Results 5/5/2016
Regeneron (REGN) Reports First Quarter 2016 Financial And Operating Results 5/5/2016
Encore Vision Announces Successful Phase I-II Study Of Topical EV06 For The Treatment Of Presbyopia 5/5/2016
Novaliq GmbH Announces Last Patient Enrolled In Phase II Clinical Trial Of Cyclasol For The Treatment Of Moderate To Severe Dry Eye Disease 5/5/2016
Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results 5/5/2016
FDA Grants Orphan Drug Designation To Allena Pharmaceuticals, Inc.’s Investigational Therapy For The Treatment Of Pediatric Hyperoxaluria 5/5/2016
Opthea Doses First Patient In Phase 2A Dose Expansion Study For OPT-302 In Wet AMD 5/5/2016
Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease 5/5/2016
Rigel (RIGL) Announces First Quarter 2016 Financial Results 5/4/2016
ORYZON Genomics Closes € 10.5 Million (12.1 M USD) Debt Financing 5/4/2016
RXi Pharma (RXII) To Present An Update On Its Consumer Health Programs At The Society For Investigative Dermatology 75th Annual Meeting 5/4/2016
VAXIMM Initiates Phase 2a Study In Advanced Colorectal Cancer With Oral T-Cell Vaccine VXM01 5/4/2016
GlycoMimetics, Inc. (GLYC) Reports First Quarter 2016 Results 5/4/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/4/2016
SELLAS Life Sciences Group Announces Positive WT1 Cancer Vaccine (Galinpepimut-S) Clinical Results At The 13th International Conference Of The International Mesothelioma Interest Group (iMig) 5/4/2016
Xencor Reports First Quarter 2016 Financial Results 5/3/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/3/2016
NeuralStem Inc. Announces Proposed Public Offering Of Securities 5/3/2016
Envisia Therapeutics Announces Positive Three-Month Interim Results Of Low Dose ENV515 In Patients With Glaucoma 5/3/2016
Tocagen Inc. Presents Intravenous Toca 511 Clinical Data At The 84th AANS Annual Scientific Meeting 5/3/2016
Mount Sinai And Galmed Pharmaceuticals To Collaborate In An Investigator Initiated Phase Ila Trial To Evaluate The Effect Of AramcholTM In Combination With Vitamin D For The Treatment Of Patients With Fibrotic Nonalcoholic Fatty Liver Disease 5/3/2016
RXi Pharma (RXII) And Thera Neuropharma Enter Into An Exclusive License Agreement For RXi's Self-Delivering RNAi (sd-rxRNA) Platform Targeting SOD1 To Develop Therapeutics For Neurodegenerative Diseases, Such As ALS (Lou Gehrig's Disease) 5/3/2016
Foamix Pharma (FOMX) Announces Completion Of Enrollment In Phase II Clinical Trial Of Minocycline Foam (FMX103) For Treatment Of Papulopustular Rosacea 5/3/2016
TG Therapeutics, Inc. (MHA) Launches First Clinical Trial In Multiple Sclerosis (MS) For TG-1101 (Ublituximab) 5/3/2016
Merrimack (MACK) Reports First Quarter 2016 Financial Results 5/3/2016
Sangamo (SGMO) Reports First Quarter 2016 Financial Results 5/3/2016
Bone Therapeutics Completes Recruitment Of Its ALLOB Phase IIA Spinal Fusion Study 5/3/2016
Ablynx (ABLYF) Reports Positive Top Line Results For Its Anti-RSV Nanobody (ALX-0171) Inhaled Using Vectura (VEC.L)’s FOX Device In A Phase I/IIa Study In Infants Hospitalized With RSV Infection 5/3/2016
NW Bio (NWBO) Announces Operations Updates 5/3/2016
Oragenics, Inc. (OGEN) Announces Positive Results From Confirmatory Animal Study Of AG013 For Treatment Of Oral Mucositis And Plans To Finalize Phase 2 Clinical Trial Protocol 5/3/2016
Trevena (TRVN) Announces Successful End-of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine 5/3/2016
Cerulean Pharma Inc. (CERU) Reports First Quarter 2016 Corporate Highlights And Financial Results 5/3/2016
Genentech (RHHBY) Highlights Personalized Medicines And Cancer Immunotherapies At 2016 ASCO Annual Meeting 5/3/2016
Array BioPharma (ARRY) Reports Financial Results For The Third Quarter Of Fiscal 2016 5/3/2016
Can-Fite BioPharma (CFBI) To Present Data On Cf602 In The Treatment Of Erectile Dysfunction At American Urological Association's Annual Meeting 5/2/2016
Tobira Announces Interim 12-Week Results From The ORION Study 5/2/2016
Parion Sciences Announces The Presentation Of Clinical Data On P-321 Ophthalmic Solution For The Treatment Of Dry Eye Disease At The Association for Research in Vision & Ophthalmology 5/2/2016



//-->